Clinical Trials Browser

Phase 1 × Active not recruiting × Stomach Neoplasms × Clear all

NCT02381561 2026-03-19

Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy

Phase 1 Active not recruiting

19 enrolled

Gastrointestinal

Colonic Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Rectal Neoplasms, Stomach Neoplasms

NCT05891171 2026-02-27

ARC-25

Phase 1 Active not recruiting

40 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT04044859 2026-02-09

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

Phase 1 Active not recruiting

120 enrolled

DermatologicGastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT05239143 2026-02-09

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

180 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Nasopharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT05867121 2026-02-02

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

Phase 1 Active not recruiting

102 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Stomach Neoplasms

NCT05156866 2026-01-13

First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer

Phase 1 Active not recruiting

163 enrolled

Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms

NCT05075993 2025-12-26

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

Phase 1 Active not recruiting

352 enrolled

DermatologicGastrointestinalGynecologicSarcoma

Uveal Melanoma, Carcinoma, Hepatocellular, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms

NCT06131398 2025-12-22

A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

77 enrolled

DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms, Colorectal Neoplasms

NCT05539430 2025-12-12

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma

Phase 1 Active not recruiting

56 enrolled

Gastrointestinal

Esophageal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT05238883 2025-11-21

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

72 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Testicular Germ Cell Tumor, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Mesothelioma, Sarcoma, Stomach Neoplasms

NCT05789069 2025-11-21

A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

83 enrolled

DermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Stomach Neoplasms, Colorectal Neoplasms

NCT06714617 2025-11-04

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

120 enrolled

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT03993873 2025-10-01

SHIELD-1

Phase 1 Active not recruiting

95 enrolled

GastrointestinalThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms

NCT03170960 2025-08-17

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

914 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

138 enrolled

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03044613 2025-03-06

Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer

Phase 1 Active not recruiting

32 enrolled

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT04660929 2024-12-18

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Phase 1 Active not recruiting

48 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Ovarian Epithelial, Adenocarcinoma, Bile Duct Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Small Cell, Carcinoma, Ductal, Small Cell Lung Carcinoma, Inflammatory Breast Neoplasms

NCT05462717 2024-11-07

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Phase 1 Active not recruiting

222 enrolled

GastrointestinalGynecologicThoracic

Appendiceal Neoplasms, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Stomach Neoplasms, Thoracic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Pancreatic Ductal

NCT04511871 2024-10-28

A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors

Phase 1 Active not recruiting

12 enrolled

BreastGastrointestinalGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms

NCT05159440 2024-10-22

First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer

Phase 1 Active not recruiting

70 enrolled

Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms

NCT04535401 2024-10-10

Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

Phase 1 Active not recruiting

10 enrolled

Gastrointestinal

Stomach Neoplasms, Colorectal Neoplasms

NCT05215574 2024-10-10

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

130 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04454476 2024-07-31

Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor

Phase 1 Active not recruiting

15 enrolled

Gastrointestinal

Metaplasia, Stomach Neoplasms

NCT03172416 2024-05-29

PIPAC

Phase 1 Active not recruiting

21 enrolled

GastrointestinalGynecologic

Peritoneal Neoplasms, Stomach Neoplasms

NCT05311618 2024-04-01

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

71 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

NCT03132922 2024-01-22

MAGE-A4ᶜ¹º³²T for Multi-Tumor

Phase 1 Active not recruiting

71 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT02496273 2016-02-22

Phase I Trial of CEA Specific AAV-DC-CTL Treatment in Stage IV Gastric Cancer

Phase 1 Active not recruiting

60 enrolled

Gastrointestinal

Stomach Neoplasms